for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sanofi SA

SASY.PA

Latest Trade

81.41EUR

Change

-0.64(-0.78%)

Volume

1,343,551

Today's Range

81.12

 - 

81.99

52 Week Range

71.74

 - 

85.90

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
82.05
Open
81.99
Volume
1,343,551
3M AVG Volume
51.16
Today's High
81.99
Today's Low
81.12
52 Week High
85.90
52 Week Low
71.74
Shares Out (MIL)
1,252.00
Market Cap (MIL)
102,799.30
Forward P/E
14.05
Dividend (Yield %)
3.69

Next Event

Q3 2019 Sanofi SA Earnings Release

Latest Developments

More

Sobi enters expanded agreement with Sanofi for development and commercialisation of BIVV001

Sanofi says the CHMP adopted a positive opinion for Dupixent

CHMP Recommends Approval Of Dupixent For Severe Chronic Rhinosinusitis With Nasal Polyposis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sanofi SA

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Industry

Biotechnology & Drugs

Contact Info

54 rue la Boetie

+33.1.53774000

https://www.sanofi.com/

Executive Leadership

Serge Weinberg

Independent Chairman of the Board

Paul Hudson

Chief Executive Officer, Member of the Executive Committee

Jean-Baptiste Chasseloup de Chatillon

Chief Financial Officer, Executive Vice President, Member of the Executive Committee

Karen Linehan

Executive Vice President - Legal Affairs and General Counsel, Member of the Executive Committee

Caroline Luscombe

Executive Vice President of Human Resources, Member of the Executive Committee

Key Stats

1.92 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

33.8K

2017

35.1K

2018

34.5K

2019(E)

36.6K
EPS (EUR)

2016

5.680

2017

5.540

2018

5.470

2019(E)

5.839
Price To Earnings (TTM)
28.69
Price To Sales (TTM)
2.80
Price To Book (MRQ)
1.82
Price To Cash Flow (TTM)
19.04
Total Debt To Equity (MRQ)
47.43
LT Debt To Equity (MRQ)
39.20
Return on Investment (TTM)
3.38
Return on Equity (TTM)
2.79

Latest News

Latest News

Mylan loses bid to axe Sanofi insulin patents ahead of trial

A federal judge on Wednesday dealt a setback to generic drug company Mylan NV in its bid to invalidate patents owned by Sanofi SA relating to its insulin drug Lantus.

Sanofi to present strategy update in December-CEO

French drugmaker Sanofi will hold an investor day to spell out the group's short and longer term strategy in December, its newly appointed chief executive said on Tuesday.

French drugmaker Sanofi to cut around 200 jobs in Japan -source

French drugmaker Sanofi SA plans to cut around 200 jobs in Japan across sales, regulatory affairs and operations, a person familiar with the matter said, months after the company said it would shed nearly 500 jobs in France and Germany.

Novartis MS drug cuts relapse rate by half compared to Sanofi medicine

Novartis's investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi's Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases.

Sanofi to pay Lexicon $260 million for terminated partnership

Lexicon Pharmaceuticals Inc said on Tuesday France's Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista.

Novo Nordisk to cut insulin prices in the U.S.

Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which sells a rival drug.

U.S. judge rules for Sanofi in Amgen patent fight

A U.S. judge on Wendesday largely set aside a jury verdict that Amgen Inc patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA. (Reporting by Jan Wolfe; editing by Jonathan Oatis)

Judge rejects Sanofi bid to exclude experts in Taxotere hair loss cases

A federal judge in New Orleans has rejected Sanofi SA's bid to exclude two expert witnesses retained by plaintiffs to help prove their claims in thousands of lawsuits that its cancer treatment Taxotere caused them to suffer permanent hair loss.

Sanofi beats bid to exclude expert ‘Trojan horse’ testimony on Taxotere risk

A federal judge has rejected a bid by patients who allege Sanofi SA's cancer treatment Taxotere caused their permanent hair loss to prevent the drugmaker from presenting expert testimony based on an ex-employee's new analysis that showed minimal such side effects.

Sanofi scores double win in Federal Circuit on Jevtana patents

A federal appeals court on Wednesday delivered a double dose of good news to Sanofi-Aventis U.S., affirming the validity of its first patent on the prostate-cancer drug Jevtana and overturning a ruling against a later patent on a method of administering it.

IN BRIEF: 10th Circuit tosses lawsuit over Clomid birth defect risk warnings

A federal appeals court has upheld the dismissal of a Utah woman's lawsuit accusing Sanofi SA of failing to warn about the risks its infertility drug Clomid posed to fetuses when taken during pregnancy.

EU approves Sanofi, Regeneron's Dupixent for adolescent eczema cases

The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won regulatory approval in Europe for moderate-to-severe cases of eczema in adolescents, the companies said.

EU regulators approve Sanofi, Regeneron's Dupixent for adolescent cases

The Dupixent product developed by French healthcare company Sanofi and its U.S. partner Regeneron has won approval in Europe for adolescents with moderate-to-severe atopic dermatitis, the companies said on Tuesday.

Sanofi raises outlook after strong second quarter

Sanofi <SASY.PA> has raised its 2019 outlook on the back of strong second-quarter results, which benefited from double-digit growth at the French drugmaker's vaccines and rare diseases businesses.

Drugmaker Sanofi raises outlook after strong Q2 numbers

Sanofi raised its 2019 outlook on the back of second-quarter results lifted by double digit growth at its vaccines and rare diseases businesses.

UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes.

Sanofi ends partnership with Lexicon to develop diabetes drug

French drugmaker Sanofi SA said on Friday it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop and manufacture a drug for use with insulin in patients with type 1 and type 2 diabetes.

Sanofi signs U.S. rights deal with Roche for flu treatment Tamiflu

French drugs and healthcare group Sanofi <SASY.PA> said on Tuesday it had signed a rights deal with Roche <ROG.S> for the 'Tamiflu' product in the United States.

Pfizer, Sanofi, to boost South African Biovac's vaccine output

South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up